Beam Therapeutics (BEAM) Could Be 50% Undervalued As Probe Follows Trial Safety Questions

Pomerantz LLP has opened an investigation into Beam Therapeutics (BEAM) after the company reported transient liver enzyme elevations in a Phase 1/2 trial of BEAM-302, a disclosure that was followed by a sharp share price drop.

For context, Beam Therapeutics shares closed at US$25.70, with a 1 day share price return of 4.47% and a 7 day share price return of 4.90%. However, the 90 day share price return is down 21.36% and the 1 year total shareholder return is down 2.36%, so near term momentum has picked up after a period of weaker performance and deep longer term losses over five years.

Stress test your thesis on Beam Therapeutics by comparing it with 31 resilient stocks with low risk scores that have held up better when legal or clinical headlines hit.

Beam Therapeutics has bounced on the latest headlines, but the chart over longer periods still shows heavy damage. Is this recent strength the start of a rebuild in value, or has most of the easy upside already passed?

Most Popular Narrative: 49.7% Undervalued

On the most followed narrative, Beam Therapeutics screens as undervalued, with a fair value of $51.07 versus the recent $25.70 close, which puts a lot of weight on its clinical and platform thesis.

The development of ESCAPE technology aims to expand the addressable patient population for gene editing by eliminating chemotherapy, which could significantly increase the market and, subsequently, revenue and margins. Beam has nominated BEAM-103 and BEAM-104 for their ESCAPE program, which could bring transformative changes in transplant medicine by enabling non-genotoxic conditioning, leading to broader patient access and a potential increase in revenue.

See why 60 investors see Beam Therapeutics as 50% undervalued.

Result: Fair Value of $51.07 (UNDERVALUED)

Still, safety setbacks around busulfan conditioning, as well as any slowdown in trial enrollment or funding, could quickly erode confidence in the current Beam Therapeutics thesis.

Find out about the key risks to this Beam Therapeutics narrative.

Another View: What Multiples Say About Beam Therapeutics

The analyst narrative around Beam Therapeutics leans heavily on future earnings and clinical success, yet the current P/S ratio of 16.5x tells a different story when lined up against the US Biotechs industry at 12.1x and a fair ratio of just 0.8x. That gap points to meaningful valuation risk if sentiment or funding conditions change again.

There is no single right way to value a biotech that is still loss making, so it can help to cross check this richer P/S against our fair ratio work on similar peers, then decide which set of assumptions feels closer to how you actually expect Beam Therapeutics to trade over the next few years.See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on Beam Therapeutics so far, right? Use that tension as a prompt to move quickly, review the upside and downside data, and ground your own view in the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Beam Therapeutics?

Do not stop with Beam Therapeutics. Broaden your watchlist with a few focused stock pools that align with different risk, income, and value preferences.

• Target resilient balance sheets by scanning a curated list of solid balance sheet and fundamentals (25 results) that can help cushion portfolio shocks when single-stock headlines hit hard.
• Hunt for potential mispricings using the 28 high quality undervalued stocks to spot companies where fundamentals and price appear out of sync.
• Build a steadier cash flow stream by reviewing the 8 dividend fortresses that focuses on higher yielding businesses with income front and center.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com